On a positive note an additional $12.6M is due from the ATO for R&D tax incentive which will swell the cash reserves to $174M.
The highlights of the operating review demonstrate how brilliant this company is about getting on with the business of developing its IP through clinical trials to realise positive outcomes for cancer patients.
As we commence Q2 we have much to look forward to with the imminent granting of FDA IND approval for the commencement of OnCARlytics trials and the presentation of results from combination trials for NextHERizon and Vaxinia.
For the knockers and nay sayers I say do your best but you won't deter the rest who understand the success that lies ahead for this company.
.
Just my opinion - GLTA and please DYOR
Ann: Half Yearly Report and Accounts, page-72
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |